REGN5381 for Heart Failure
(NATRIX-BNP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).The aim of the study is to see how safe, tolerable, and effective the study drug is.The study is looking at several other research questions, including:* What side effects may happen from taking the study drug* How much study drug is in the blood at different times* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Who Is on the Research Team?
Clinical Trials Administrator
Principal Investigator
Regeneron Pharmaceuticals
Are You a Good Fit for This Trial?
This trial is for adults with chronic heart failure where the heart's pumping power is reduced (ejection fraction of 20-49%). Participants must have a BMI between 18 and 40, high levels of NT-proBNP in their blood, and be on optimized standard heart failure therapy. People with certain kidney function levels can join specific subgroups.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of REGN5381 or placebo to evaluate safety, pharmacokinetics, and pharmacodynamics
Follow-up
Participants are monitored for safety, side effects, and antibody development against the study drug
What Are the Treatments Tested in This Trial?
Interventions
- REGN5381
Find a Clinic Near You
Who Is Running the Clinical Trial?
Regeneron Pharmaceuticals
Lead Sponsor
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer since 1988
MD and PhD in Medicine
George Yancopoulos
Regeneron Pharmaceuticals
Chief Medical Officer since 1997
MD from Harvard Medical School